A Phase III, Randomized, Double-Blind, Placebo Controlled, Multicenter, 3-Period, 14-Day Crossover Study to Determine the 24-h Lung Function Profile of Indacaterol (300 microg once daily) in Patients With Moderate-to-Severe COPD, Using Open-Label Salmeterol (50 microg twice per day) as Active Control

Trial Profile

A Phase III, Randomized, Double-Blind, Placebo Controlled, Multicenter, 3-Period, 14-Day Crossover Study to Determine the 24-h Lung Function Profile of Indacaterol (300 microg once daily) in Patients With Moderate-to-Severe COPD, Using Open-Label Salmeterol (50 microg twice per day) as Active Control

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Nov 2014

At a glance

  • Drugs Indacaterol (Primary) ; Salmeterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 04 Nov 2009 Primary endpoint 'Forced-expiratory-volume-in-1-second' has been met.
    • 04 Nov 2009 Results reported at the 75th Annual Meeting of the American College of Chest Physicians: Chest 2009.
    • 10 Jul 2009 Actual patient number (68) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top